|
NOVEN PRESENTS PRE-CLINICAL STUDY DATA AT AAPS ANNUAL MEETING |
BackMiami, FL, November
19, 2002 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) announced that
it presented the results of several pre-clinical transdermal research
projects at the recent 2002 American Association of Pharmaceutical Scientists
(AAPS) Annual Meeting and Exposition. The full text of these presentations
is available on Noven’s website at www.noven.com under "Research/Scientific
Publications."
"We are very pleased with the results of our ongoing pre-clinical
development programs," said Juan Mantelle, Noven’s Chief Technical
Officer. "The AAPS presentations represent just a small portion of
our comprehensive development efforts, and reflect Noven’s commitment
to advancing transdermal science and to maintaining a robust new product
pipeline."
At the AAPS meeting, David Kanios, Noven’s Associate Director –
Research & Development, presented "In-Vitro
Permeation of Low Molecular Weight Amine Drugs in Transdermal Drug Delivery
Systems." The presentation summarized the results of three
pre-clinical studies designed to establish formulation parameters for
the transdermal delivery of methamphetamine and d-amphetamine, which could
be used in the treatment of Attention-Deficit Hyperactivity Disorder (ADHD).
Study results indicated that varying the ratios of acrylic and silicone
pressure sensitive adhesives allows flexibility to attain a desired profile
for the delivery of both methamphetamine and d-amphetamine via an adhesive
matrix transdermal system.
David Houze, Noven Senior Research Scientist, presented the results of
a study entitled "In-Vitro Transdermal Permeation
Performance of Drug and Pro-drug Combinations." Using norethindrone
and norethindrone acetate, this study demonstrated that higher skin permeation
rates than those obtained from a single-drug formulation can be achieved
with the addition of a pro-drug to the adhesive matrix.
Chensheng Li, Noven Senior Research Chemist, presented the results of
a study entitled "Kinetic Study of Threo-Methylphenidate
Degradation Reaction to Erythro Isomer in MethyPatch Transdermal System,"
which supported the use of an accelerated three-month model to accurately
test the stability of a transdermal methylphenidate system, and possibly
other transdermal systems.
Viet T. Nguyen, Noven Process Development Engineer, presented the results
of a study entitled "In-Vitro to In-Vivo Evaluation
for Scopolamine Transdermal Delivery." This study demonstrated
the correlation between Noven’s in vitro delivery model and actual
in vivo plasma concentrations for transdermal scopolamine, and helped
refine Noven’s overall in vitro/in vivo modeling capabilities.
"Noven's transdermal technology has expanded the universe of molecules
that can be delivered transdermally, making patch formulations possible
in a broad range of therapeutic categories," said Pavan Handa, Noven's
Executive Director – Business Development. "This has created
an abundance of development opportunities for Noven and for third party
licensees. Our continuing business development goal is to strike mutually
beneficial development and license arrangements, and we welcome inquiries
and proposals in this regard."
The majority of Noven's development projects utilize Noven's patented
DOT Matrix™ transdermal patch technology, which is the delivery platform
underlying the Vivelle-Dot® and CombiPatch®
hormone therapy patches, and MethyPatch®, Noven's developmental
transdermal methylphenidate patch for ADHD (New Drug Application pending).
DOT Matrix technology permits Noven to deliver predictable therapeutic
doses of a wide range of prescription therapies through discreet, comfortable
and adherent patches that are well suited to active lifestyles.
About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading
developer of advanced transdermal drug delivery technologies and prescription
transdermal products. Noven's existing products include advanced estrogen
transdermal delivery systems (including Vivelle-Dot®, licensed
to Novogyne Pharmaceuticals, and Estradot®, licensed to
Novartis Pharma AG) and combination estrogen/progestin transdermal delivery
systems (including CombiPatch®, licensed to Novogyne Pharmaceuticals,
and Estalis®, licensed to Novartis Pharma AG). With a range
of additional products in development, including MethyPatch®
for Attention-Deficit Hyperactivity Disorder, Noven is committed to becoming
the world's premier developer, manufacturer and marketer of transdermal
drug delivery systems. For additional information on Noven, visit www.noven.com.
Contact:
Investors & Media
Joseph C. Jones
Vice President, – Corporate Affairs
Noven Pharmaceuticals, Inc.
(305) 253-1916
Business Development
& Licensing
Pavan Handa
Executive Director – Business Development
(305) 964-3330
Copyright © 2002 Noven Pharmaceuticals, Inc. All rights reserved.